Zimbabwe has rejected a major American health deal valued at 367 million US dollars (£272m) over five years due to the United States' demand for confidential data.
This move was revealed after a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson later explained that the United States was requesting biological samples for research and profit while was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further talks to secure a deal agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Implications
This development follows a similar situation in neighbouring Kenya, where a court halted a similar deal with the US after concerns were raised about the security of Kenyans' health data.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost transparency and responsibility.
According to reports, Sixteen African countries have to date agreed to similar health pacts, representing over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information for a long time, without any equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our population should a new pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting systems previously established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This mechanism is designed to ensure that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future co-operation could be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
A leading public health body stated it acknowledged the official position, but recommended that negotiations should continue since a large portion of the country's HIV programmes depended on international support.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it added.
The situation underscores the complex tensions between receiving much-needed foreign assistance and protecting a country's data in an ever more data-driven world.